Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jennifer Van Eyk, George Scangos


Jennifer Van Eyk has been named the inaugural director of Cedars-Sinai's Advanced Clinical Biosystems Research Institute, Cedars-Sinai said this week. She also will lead basic research at the Cedars-Sinai Barbara Streisand Women's Heart Center.

Van Eyk joins Cedars-Sinai from Johns Hopkins University School of Medicine. A proteomics investigator, she is known for developing lab tests to determine the presence of proteins in blood that could indicate whether a patient has experienced a heart attack or has heart disease. She will remain director of the National Heart Lung and Blood Institute Proteomic Innovation Center on Heart Failure, a contract NHLBI awarded to her group at Johns Hopkins.

Agilent said this week that it has appointed Biogen Idec CEO George Scangos to its board of directors, effective September.

Prior to Biogen, Scangos served as president and CEO of Exelixis, a drug discovery and development company. He was previously president of Bayer Biotechnology.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.